{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:57:50Z","timestamp":1781873870383,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000406","name":"Motor Neurone Disease Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014012","name":"FightMND","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["T003519N"],"award-info":[{"award-number":["T003519N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014076","name":"Stichting ALS Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018007","name":"Ulla-Carin Lindquists stiftelse f\u00f6r ALS-forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018007","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009281","name":"Fondation Thierry Latran","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009281","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n Francisco Luzon"},{"name":"Alan Davidson Foundation"},{"name":"My Name'5 Doddie Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Given the large genetic heterogeneity in amyotrophic lateral sclerosis (ALS), it seems likely that genetic subgroups may benefit differently from treatment. An exploratory meta-analysis identified that patients homozygous for the C-allele at SNP rs12608932, a single nucleotide polymorphism in the gene <jats:italic>UNC13A<\/jats:italic>, had a statistically significant survival benefit when treated with lithium carbonate. We aim to confirm the efficacy of lithium carbonate on the time to death or respiratory insufficiency in patients with ALS homozygous for the C-allele at SNP rs12608932 in <jats:italic>UNC13A<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A randomized, group-sequential, event-driven, double-blind, placebo-controlled trial will be conducted in 15 sites across Europe and Australia. Patients will be genotyped for <jats:italic>UNC13A<\/jats:italic>; those homozygous for the C-allele at SNP rs12608932 will be eligible. Patients must have a diagnosis of ALS according to the revised El Escorial criteria, and a TRICALS risk-profile score between \u22126.0 and \u22122.0. An expected number of 1200 patients will be screened in order to enroll a target sample size of 171 patients. Patients will be randomly allocated in a 2:1 ratio to lithium carbonate or matching placebo, and treated for a maximum duration of 24 months. The primary endpoint is the time to death or respiratory insufficiency, whichever occurs first. Key secondary endpoints include functional decline, respiratory function, quality of life, tolerability, and safety. An interim analysis for futility and efficacy will be conducted after the occurrence of 41 events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Lithium carbonate has been proven to be safe and well-tolerated in patients with ALS. Given the favorable safety profile, the potential benefits are considered to outweigh the burden and risks associated with study participation. This study may provide conclusive evidence about the life-prolonging potential of lithium carbonate in a genetic ALS subgroup.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EudraCT number <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000579-19\/NL\">2020-000579-19<\/jats:ext-link>. Registered on 29 March 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06906-5","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T08:03:23Z","timestamp":1670227403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0198-5740","authenticated-orcid":false,"given":"Sean W.","family":"Willemse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kit C. B.","family":"Roes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Hardiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ingre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Povedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi R.","family":"Wray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Gijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam S.","family":"de Pagter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen C.","family":"Demaegd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie F. C.","family":"Janse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel G.","family":"Vink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn T. H. M.","family":"Sleutjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Chi\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Corcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evy","family":"Reviers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Al-Chalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Kiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard H.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"van Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben P. A.","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"issue":"10107","key":"6906_CR1","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","volume":"390","author":"MA van Es","year":"2017","unstructured":"van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084\u201398.","journal-title":"Lancet."},{"issue":"2","key":"6906_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162\u201372.","journal-title":"N Engl J Med"},{"issue":"5","key":"6906_CR3","doi-asserted-by":"publisher","first-page":"E451","DOI":"10.1212\/WNL.0000000000006855","volume":"92","author":"RPA Van Eijk","year":"2019","unstructured":"Van Eijk RPA, Westeneng HJ, Nikolakopoulos S, Verhagen IE, Van Es MA, Eijkemans MJC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):E451\u201360.","journal-title":"Neurology."},{"issue":"12","key":"6906_CR4","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s00415-006-0195-y","volume":"253","author":"CA Johnston","year":"2006","unstructured":"Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AHM, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: A population based study of inner city London. J Neurol. 2006;253(12):1642\u20133.","journal-title":"J Neurol"},{"issue":"9013","key":"6906_CR5","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","volume":"347","author":"L Lacomblez","year":"1996","unstructured":"Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347(9013):1425\u201331.","journal-title":"Lancet."},{"issue":"2","key":"6906_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41582-020-00434-z","volume":"17","author":"MC Kiernan","year":"2021","unstructured":"Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104\u201318.","journal-title":"Nat Rev Neurol"},{"issue":"7\u20138","key":"6906_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/21678421.2020.1788092","volume":"21","author":"RPA van Eijk","year":"2020","unstructured":"van Eijk RPA, Kliest T, McDermott CJ, Roes KCB, Van Damme P, Chio A, et al. TRICALS: creating a highway toward a cure. Amyotroph Lateral Scler Front Degener. 2020;21(7\u20138):496\u2013501.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"18","key":"6906_CR8","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1212\/WNL.0000000000004606","volume":"89","author":"RPA Van Eijk","year":"2017","unstructured":"Van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89(18):1915\u201322.","journal-title":"Neurology."},{"issue":"10","key":"6906_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.5694\/j.1326-5377.1949.tb36912.x","volume":"2","author":"JFJ Cade","year":"1949","unstructured":"Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349\u201352.","journal-title":"Med J Aust"},{"issue":"4","key":"6906_CR10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1136\/jnnp.17.4.250","volume":"17","author":"M Schou","year":"1954","unstructured":"Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry. 1954 Nov;17(4):250\u201360.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"6906_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/jnnp-2019-322382","volume":"91","author":"AJ Lees","year":"2020","unstructured":"Lees AJ. Lithium: A slow burner. J Neurol Neurosurg Psychiatry. 2020;91(4):335\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"6906_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1021\/cn5000309","volume":"5","author":"OV Forlenza","year":"2014","unstructured":"Forlenza OV, De-Paula VJR, Diniz BSO. Neuroprotective effects of lithium: Implications for the treatment of Alzheimer\u2019s disease and related neurodegenerative disorders. ACS Chem Neurosci. 2014;5(6):443\u201350.","journal-title":"ACS Chem Neurosci"},{"issue":"8","key":"6906_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1042\/BC20100036","volume":"102","author":"JHP Broeke","year":"2010","unstructured":"Broeke JHP, Roelandse M, Luteijn MJ, Boiko T, Matus A, Toonen RF, et al. Munc18 and Munc13 regulate early neurite outgrowth. Biol Cell. 2010;102(8):479\u201388.","journal-title":"Biol Cell"},{"issue":"4","key":"6906_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1474-4422(13)70037-1","volume":"12","author":"A Al-Chalabi","year":"2013","unstructured":"Al-Chalabi A, Allen C, Counsell C, Farrin A, Dickie B, Kelly J, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): A phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(4):339\u201345.","journal-title":"Lancet Neurol"},{"issue":"5","key":"6906_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/jnnp-2011-302021","volume":"83","author":"E Verstraete","year":"2012","unstructured":"Verstraete E, Veldink JH, Huisman MHB, Draak T, Uijtendaal EV, Van Der Kooi AJ, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: A phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry. 2012;83(5):557\u201364.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"6906_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293\u20139.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"6906_CR17","unstructured":"TRICALS. Risk Profile Calculator. https:\/\/tricals.shinyapps.io\/risk-profile\/. Accessed 21 Sep 2022."},{"issue":"11","key":"6906_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/WNL.0000000000012545","volume":"97","author":"RPA van Eijk","year":"2021","unstructured":"van Eijk RPA, Nikolakopoulos S, Roes KCB, Kendall L, Han SS, Lavrov A, et al. Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order. Neurology. 2021;97(11):528\u201336.","journal-title":"Neurology."},{"issue":"5","key":"6906_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","volume":"17","author":"HJ Westeneng","year":"2018","unstructured":"Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423\u201333.","journal-title":"Lancet Neurol"},{"issue":"7","key":"6906_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1212\/WNL.0b013e3181ed9e7c","volume":"75","author":"A Chi\u00f2","year":"2010","unstructured":"Chi\u00f2 A, Borghero G, Calvo A, Capasso M, Caponnetto C, Corbo M, et al. Lithium carbonate in amyotrophic lateral sclerosis: Lack of efficacy in a dose-finding trial. Neurology. 2010;75(7):619\u201325.","journal-title":"Neurology."},{"key":"6906_CR21","first-page":"231","volume":"9","author":"P Haddad","year":"1999","unstructured":"Haddad P, Wieck A, Yarrow M, Denham P. The Lithium Side Effects Rating Scale (LISERS); development of a self-rating instrument. Eur Neuropsychopharmacol. 1999 Sep;9:231\u20132.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1\u20132","key":"6906_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","volume":"169","author":"JM Cedarbaum","year":"1999","unstructured":"Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1\u20132):13\u201321.","journal-title":"J Neurol Sci"},{"issue":"1","key":"6906_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1212\/01.WNL.0000148648.38313.64","volume":"64","author":"P Kaufmann","year":"2005","unstructured":"Kaufmann P, Levy G, Thompson JLP, DelBene ML, Battista V, Gordon PH, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64(1):38\u201343.","journal-title":"Neurology."},{"issue":"3","key":"6906_CR24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/jnnp.2005.072660","volume":"77","author":"A Czaplinski","year":"2006","unstructured":"Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77(3):390\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"6906_CR25","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1183\/13993003.01757-2016","volume":"48","author":"PH Quanjer","year":"2016","unstructured":"Quanjer PH, Stanojevic S. Do the global lung function initiative 2012 equations fit my population? Eur Respir J. 2016;48(6):1782\u20135.","journal-title":"Eur Respir J"},{"issue":"2","key":"6906_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp-2017-317077","volume":"89","author":"RPA Van Eijk","year":"2018","unstructured":"Van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, Van Den Berg LH. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2018;89(2):156\u201361.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"6906_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ane.12134","volume":"128","author":"S Tetsuka","year":"2013","unstructured":"Tetsuka S, Morita M, Ikeguchi K, Nakano I. Utility of cystatin C for renal function in amyotrophic lateral sclerosis. Acta Neurol Scand. 2013;128(6):386\u201390.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"6906_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/jnnp-2013-306589","volume":"86","author":"A Chi\u00f2","year":"2015","unstructured":"Chi\u00f2 A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):38\u201344.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"6906_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/jnnp-2013-306865","volume":"86","author":"R Balendra","year":"2015","unstructured":"Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw PJ, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry. 2015;86(1):45\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6906_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2018.00442","volume":"9","author":"X Chen","year":"2018","unstructured":"Chen X, Wei QQ, Chen Y, Cao B, Ou RW, Hou Y, et al. Clinical staging of amyotrophic lateral sclerosis in Chinese patients. Front Neurol. 2018;9:1\u20139.","journal-title":"Front Neurol"},{"issue":"12","key":"6906_CR31","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1212\/WNL.0000000000003741","volume":"88","author":"SR Shepheard","year":"2017","unstructured":"Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, et al. Urinary p75ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88(12):1137\u201343.","journal-title":"Neurology."},{"issue":"22","key":"6906_CR32","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","volume":"84","author":"CH Lu","year":"2015","unstructured":"Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247\u201357.","journal-title":"Neurology."},{"issue":"15","key":"6906_CR33","doi-asserted-by":"publisher","first-page":"E1370","DOI":"10.1212\/WNL.0000000000006317","volume":"91","author":"C Crockford","year":"2018","unstructured":"Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018;91(15):E1370\u201380.","journal-title":"Neurology."},{"issue":"1\u20132","key":"6906_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/21678421.2013.805784","volume":"15","author":"S Abrahams","year":"2014","unstructured":"Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Front Degener. 2014;15(1\u20132):9\u201314.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"13","key":"6906_CR35","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1212\/WNL.0b013e31826c1aa1","volume":"79","author":"J Raaphorst","year":"2012","unstructured":"Raaphorst J, Beeldman E, Schmand B, Berkhout J, Linssen WHJP, Van Den Berg LH, et al. The ALS-FTD-Q: A new screening tool for behavioral disturbances in ALS. Neurology. 2012;79(13):1377\u201383.","journal-title":"Neurology."},{"issue":"2","key":"6906_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1023\/B:QURE.0000018499.64574.1f","volume":"13","author":"AGEM De Boer","year":"2004","unstructured":"De Boer AGEM, Van Lanschot JJB, Stalmeier PFM, Van Sandick JW, Hulscher JBF, De Haes JCJM, et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res. 2004;13(2):311\u201320.","journal-title":"Qual Life Res"},{"issue":"3\u20134","key":"6906_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3109\/21678421.2013.872149","volume":"15","author":"AR Jones","year":"2014","unstructured":"Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, et al. Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2014;15(3\u20134):285\u201391.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"3","key":"6906_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/21678421.2012.732079","volume":"14","author":"EM Maathuis","year":"2013","unstructured":"Maathuis EM, Drenthen J, Van Doorn PA, Visser GH, Blok JH. The CMAP scan as a tool to monitor disease progression in ALS and PMA. Amyotroph Lateral Scler Front Degener. 2013;14(3):217\u201323.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"1","key":"6906_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/mus.20561","volume":"34","author":"RD Henderson","year":"2006","unstructured":"Henderson RD, Ridall GR, Pettitt AN, McCombe PA, Daube JR. The stimulus-response curve and motor unit variability in normal subjects and subjects with amyotrophic lateral sclerosis. Muscle Nerve. 2006;34(1):34\u201343.","journal-title":"Muscle Nerve"},{"issue":"2","key":"6906_CR40","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/mus.20805","volume":"36","author":"RD Henderson","year":"2007","unstructured":"Henderson RD, Ridall PG, Hutchinson NM, Pettitt AN, McCombe PA. Bayesian statistical mune method. Muscle Nerve. 2007;36(2):206\u201313.","journal-title":"Muscle Nerve"},{"issue":"2","key":"6906_CR41","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.clinph.2013.07.016","volume":"125","author":"BTHM Sleutjes","year":"2014","unstructured":"Sleutjes BTHM, Montfoort I, Maathuis EM, Drenthen J, van Doorn PA, Visser GH, et al. CMAP scan discontinuities: Automated detection and relation to motor unit loss. Clin Neurophysiol. 2014;125(2):388\u201395.","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"6906_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/jns5.12003","volume":"18","author":"J Drenthen","year":"2013","unstructured":"Drenthen J, Maathuis EM, Visser GH, van Doorn PA, Blok JH, Jacobs BC. Limb motor nerve dysfunction in Miller Fisher syndrome. J Peripher Nerv Syst. 2013;18(1):25\u20139.","journal-title":"J Peripher Nerv Syst"},{"key":"6906_CR43","first-page":"1","volume":"7","author":"EM Maathuis","year":"2012","unstructured":"Maathuis EM, Henderson RD, Drenthen J, Hutchinson NM, Daube JR, Blok JH, et al. Optimal stimulation settings for CMAP scan registrations. J Brachial Plexus Peripheral Nerve Inj. 2012;7:1\u20137.","journal-title":"J Brachial Plexus Peripheral Nerve Inj"},{"issue":"1","key":"6906_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/mus.26304","volume":"59","author":"AB Jacobsen","year":"2019","unstructured":"Jacobsen AB, Bostock H, Tankisi H. Following disease progression in motor neuron disorders with 3 motor unit number estimation methods. Muscle Nerve. 2019;59(1):82\u20137.","journal-title":"Muscle Nerve"},{"issue":"12","key":"6906_CR45","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1016\/j.clinph.2012.04.022","volume":"123","author":"F Baumann","year":"2012","unstructured":"Baumann F, Henderson RD, Ridall PG, Pettitt AN, McCombe PA. Use of Bayesian MUNE to show differing rate of loss of motor units in subgroups of ALS. Clin Neurophysiol. 2012;123(12):2446\u201353.","journal-title":"Clin Neurophysiol"},{"issue":"12","key":"6906_CR46","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1016\/j.clinph.2021.09.014","volume":"132","author":"BTHM Sleutjes","year":"2021","unstructured":"Sleutjes BTHM, Bystrup Jacobsen A, Tankisi H, Gorkem Sirin N, Emre Oge A, Henderson RD, et al. Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan. Clin Neurophysiol. 2021;132(12):3152\u20139.","journal-title":"Clin Neurophysiol"},{"key":"6906_CR47","unstructured":"TRICALS. Register as a patient in the TRICALS registry. https:\/\/www.tricals.org\/register-castor\/. Accessed 29 Sep 2022."},{"issue":"6","key":"6906_CR48","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations. Eur Respir J. 2012;40(6):1324\u201343.","journal-title":"Eur Respir J"},{"issue":"2","key":"6906_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1212\/01.wnl.0000194316.91908.8a","volume":"66","author":"F Kimura","year":"2006","unstructured":"Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265\u20137.","journal-title":"Neurology."},{"key":"6906_CR50","volume-title":"Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry","author":"Center for Drug Evaluation and Research","year":"2019","unstructured":"Center for Drug Evaluation and Research. Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry. 2019. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry. Accessed 23 Sep 2022."},{"key":"6906_CR51","volume-title":"Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS)","author":"European Medicines Agency - Committee for Medicinal Products for Human Use","year":"2015","unstructured":"European Medicines Agency - Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS). 2015. https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis. Accessed 26 Sep 2022."},{"key":"6906_CR52","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/CLEP.S153196","volume":"10","author":"RPA van Eijk","year":"2018","unstructured":"van Eijk RPA, Eijkemans MJC, Rizopoulos D, van den Berg LH, Nikolakopoulos S. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol. 2018;10:333\u201341.","journal-title":"Clin Epidemiol"},{"key":"6906_CR53","doi-asserted-by":"publisher","DOI":"10.1201\/b12208","volume-title":"Joint models for longitudinal and time-to-event data\u00a0: with applications in R","author":"D Rizopoulos","year":"2012","unstructured":"Rizopoulos D. Joint models for longitudinal and time-to-event data\u00a0: with applications in R. Boca Raton: Chapman & Hall\/CRC; 2012."},{"issue":"12","key":"6906_CR54","first-page":"1331","volume":"90","author":"RPA Van Eijk","year":"2019","unstructured":"Van Eijk RPA, Nikolakopoulos S, Roes KCB, Middelkoop BM, Ferguson TA, Shaw PJ, et al. Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2019;90(12):1331\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"6906_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mus.27091","volume":"63","author":"S Paganoni","year":"2021","unstructured":"Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31\u20139.","journal-title":"Muscle Nerve"},{"issue":"12","key":"6906_CR56","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099\u2013110.","journal-title":"N Engl J Med"},{"issue":"4","key":"6906_CR57","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/brain\/awab472","volume":"145","author":"K Salmon","year":"2022","unstructured":"Salmon K, Kiernan MC, Kim SH, Andersen PM, Chio A, Van Den Berg LH, et al. The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain. 2022;145(4):1207\u201310.","journal-title":"Brain."},{"issue":"12","key":"6906_CR58","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41588-021-00973-1","volume":"53","author":"W van Rheenen","year":"2021","unstructured":"van Rheenen W, van der Spek RAA, Bakker MK, van Vugt JJFA, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53(12):1636\u201348.","journal-title":"Nat Genet"},{"issue":"10","key":"6906_CR59","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/ng.442","volume":"41","author":"MA Van Es","year":"2009","unstructured":"Van Es MA, Veldink JH, Saris CGJ, Blauw HM, Van Vught PWJ, Birve A, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41(10):1083\u20137.","journal-title":"Nat Genet"},{"issue":"3","key":"6906_CR60","doi-asserted-by":"publisher","first-page":"630.e3","DOI":"10.1016\/j.neurobiolaging.2011.10.029","volume":"33","author":"FP Diekstra","year":"2012","unstructured":"Diekstra FP, van Vught PWJ, van Rheenen W, Koppers M, Pasterkamp RJ, van Es MA, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(3):630.e3\u20138.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"6906_CR61","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/ana.25841","volume":"88","author":"HHG Tan","year":"2020","unstructured":"Tan HHG, Westeneng HJ, van der Burgh HK, van Es MA, Bakker LA, van Veenhuijzen K, et al. The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral Sclerosis. Ann Neurol. 2020;88(4):796\u2013806.","journal-title":"Ann Neurol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06906-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06906-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06906-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T19:05:03Z","timestamp":1670267103000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06906-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6906"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06906-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"assertion":[{"value":"5 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was granted on the 25th of June 2021 by the Institutional Review Board of the UMC Utrecht, the Netherlands, with reference number 21-215. Written, informed consent to participate will be obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"The model consent form can be provided on request. No reference will be made to individual patients in any publication relating to the current trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"SWW, KCBR, OH, CI, MP, NRW, MG, MdP, KCD, AFCJ, RGV, BTHMS, PC, ER, AAC, and RPAvE declare no competing interests. PVD has served in advisory boards for Biogen, CSL Behring, Alexion Pharmaceuticals, Ferrer, QurAlis, Cytokinetics, Argenx, UCB, Muna Therapeutics, Alector, Augustine Therapeutics, and VectorY (paid to institution). AC serves on scientific advisory boards for Mitsubishi Tanabe, Biogen, Roche, Denali Pharma, Cytokinetics, Lilly, and Amylyx Pharmaceuticals and has received a research grant from Biogen. MCK is funded by the National Health and Medical Research Council of Australia Program Grant (#1132524), Partnership Project (#1153439) and Practitioner Fellowship (1156093).LHvdB declares fees to his institution from Biogen, Wave, Amylyx, Ferrer, and Cytokinetics for being on a scientific advisory board; fees to his institution from Amylyx for a lecture; an unrestricted educational grant from Takeda; and is the Chair of ENCALS and TRICALS. MAvE has consulted for Biogen, and has received travel grants from Shire (formerly Baxalta) and serves as medical monitor for Ferrer in the ADORE trial (NCT05178810), other funding sources include the Netherlands Organization for Health Research and Development (Vidi scheme), The Thierry Latran Foundation, Motor Neurone Disease Association, FIGHT-MND and the ALS Foundation Netherlands. Several authors of this publication are member of the European Reference Network for Rare Neuromuscular Diseases (ERN-NMD).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"978"}}